

THE MORAL LIMITS OF MEDICAL RESEARCH WITH CHILDREN

Anna Eva Westra

The project was supported by a grant from ZonMw, the Netherlands Organization for Health Research and Development (grant number 92003475).

A research visit to the Department of Bioethics of the National Institutes of Health, Bethesda, United States, and to the Department of Philosophy, University of Western Ontario, London, Canada, was supported by a grant from the Van Walree Fund.

The printing of this thesis was financially supported by the Department of Pediatrics of the Leiden University Medical Center and by the J.E. Jurriaanse Stichting.

Cover picture: Peter Hilz / Hollandse Hoogte

Lay-out and printing: Off Page (www.offpage.nl)

ISBN: 978-94-90371-80-7

Copyright 2011, Anna E. Westra, Amsterdam. All rights reserved. No part of this publication may be reproduced in any form or by any means without prior permission of the author.

THE MORAL LIMITS OF MEDICAL RESEARCH WITH CHILDREN

Proefschrift

ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof.mr. P.F. van der Heijden,
volgens besluit van het College voor Promoties
te verdedigen op donderdag 30 juni 2011
klokke 16.15 uur

door

Anna Eva Westra
geboren te Amsterdam in 1979

PROMOTIECOMMISSIE

Promotores: Prof. dr. J. M. Wit
Prof. dr. I. D. de Beaufort (Erasmus MC, Rotterdam)

Co-promotor: Dr. R. N. Sukhai

Overige leden: Prof. mr. dr. D. P. Engberts
Prof. dr. A. F. Cohen
Prof. dr. F. J. Walther
Prof. dr. E. van Leeuwen (UMC St. Radboud, Nijmegen)

CONTENTS

Chapter 1	General introduction	7
Chapter 2	Acceptable risks and burdens for children in research without direct benefit: a systematic analysis of the decisions made by the Dutch Central Committee	23
Chapter 3	The merits of procedure-level risk-benefit assessment	35
Chapter 4	How best to define the concept of minimal risk	49
Chapter 5	Perceived discomfort levels in healthy children participating in vaccine research	61
Chapter 6	Discomfort in children undergoing unsedated MRI	71
Chapter 7	Drug development for children: how adequate is the current European ethical guidance?	83
Chapter 8	Regulating 'higher risk, no direct benefit' studies with children	93
Chapter 9	General discussion	109
Chapter 10	Summary	125
Appendices	Appendix 1: Example studies	133
	Appendix 2: WMO	137
	Appendix 3: Checklists	141
Addendum	References	145
	Abbreviations	152
	Samenvatting	153
	Dankwoord	157
	Curriculum Vitae	159
	Publications	160